Cancer Vaccines 2004 opening address: The molecular and cellular basis of cancer immunosurveillance and immunoediting

Cancer Immunity

Volumn 5, Issue SUPPL. 1, 2005, Pages

  Schreiber, Robert D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer immunoediting; Cancer immunosurveillance; Immunotherapy; Interferon; Lymphocytes

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 12; PERFORIN; RAG2 PROTEIN; STAT1 PROTEIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOCARCINOMA; ADENOMA; AGING; ANTIGEN RECOGNITION; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SUSCEPTIBILITY; CANCER TRANSPLANTATION; CARCINOGENESIS; CYSTADENOMA; GENE TARGETING; HARDER GLAND; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; INNATE IMMUNITY; INTESTINE CARCINOMA; LUNG ADENOCARCINOMA; MOUSE MUTANT; NATURAL KILLER CELL; NONHUMAN; SARCOMA; SARCOMA CELL; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

EID: 21844459726     PISSN: 14249634     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
2. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-60.
3. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48.
4. Algarra I, Cabrera T, Garrido F. The HLA crossroad in tumor immunology. Hum Immunol 2000; 61: 65-73.
5. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
6. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000; 21: 455-64.
7. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002; 99: 16168-73.
8. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3: 999-1005.
9. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-8.
10. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Padhajcer OL, Rabinovitch GA. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5: 241-51.
11. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-74.
12. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59: 3128-33.
13. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-8.
14. Nishikawa H, Kato T, Tanida K, Hiasa A, Tawara I, Ikeda H, Ikarashi Y, Wakasugi H, Kronenberg M, Nakatama T, Taniguchi M, Kuribayashi K, Old LJ, Shiku H. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci U S A 2003; 100: 10902-6.
15. Old LJ. Immunotherapy for cancer. Sci Am 1996; 275: 136-43.
16. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281-7.
17. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000; 97: 12198-203.
18. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004; 305: 200-5.
19. Skipper J, Hoffman EW, O'Donnell-Tormey J, Old LJ. Translation of cancer immunotherapies. Nat Med 2004; 10: 1154-5.
20. Pardoll D, Allison J. Translation of cancer immunotherapies. Nat Med 2004; 10: 1155.
21. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 611-8.
22. Dranoff G. CTAL-4 blockade: unveiling immune regulation. J Clin Oncol 2005; 23: 662-4.
23. Bendelac A. Natural and synthetic antigenic ligands of NKT cells and their role in anti-tumor rejection. Cancer Immun 2005; 5 Suppl 1: 2. URL: http://www.cancerimmunity.org/v5suppl1p2/041223_abs.htm
24. Cerundolo V. Role of NKT cells to assist priming of antigen-specific T-cell response. Cancer Immun 2005; 5 Suppl 1: 3. URL: http://www. cancerimmunity.org/v5suppl1p3/041224_abs.htm
25. Lanier LL. NKG2D-mediated immune responses. Cancer Immun 2005; 5 Suppl 1: 6. URL: http://www.cancerimmunity.org/v5suppl1p6/041227_abs.htm
26. Spies T. Relevance of NKG2D and its ligands in tumor immunity. Cancer Immun 2005; 5 Suppl 1: 10. URL: http://www.cancerimmunity.org/v5suppl1p10/ 041231_abs.htm
27. Cui Z. "Magic bullets" against cancer cells in cancer-resistant SR/CR mice. CanCancer Immun 2005; 5 Suppl 1: 8. URL: http://www.cancerimmunity. org/v5suppl1p8/041229_abs.htm
28. Sakaguchi S, Yamaguchi T, Nishioka T, Ko K, Yamazaki S, Nakamura K, Hirota K, Nomura T. Natural CD4+ regulatory T cells in tumor immunity. Cancer Immun 2005; 5 Suppl 1: 4. URL: http://www.cancerimmunity.org/v5suppl1p4/ 041225_abs.htm
29. Shiku H. Regulatory T cells recognizing SEREX-defined selfantigens in anti-tumor immune response. Cancer Immun 2005; 5 Suppl 1: 5. URL: http://www.cancerimmunity.org/v5suppl1p5/041226_abs.htm
30. Allison JP. Blockade of T cell inhibitory signals: a new paradigm in tumor immunotherapy? Cancer Immun 2005; 5 Suppl 1: 9. URL: http://www. cancerimmunity.org/v5suppl1p9/041230_abs.htm
31. Valmori D. SSX antigens as cancer vaccines. Cancer Immun 2005; 5 Suppl 1: 18. URL: http://www.cancerimmunity.org/v5suppl1p18/041239_abs.htm
32. Jotereau F. Cross-presentation: a mechanism used by melanoma cells for the generation of a tumor-specific antigen derived from the matrix metalloproteinase 2. Cancer Immun 2005; 5 Suppl 1: 19. URL: http://www. cancerimmunity.org/v5suppl1p19/041240_abs.htm
33. Chen WF. Identification and characterization of human hepatocellular carcinoma-associated antigens. Cancer Immun 2005; 5 Suppl 1: 21. URL: http://www.cancerimmunity.org/v5suppl1p21/041242_abs.htm
34. Güre AO. Immunity to SOX group B and ZIC2 antigens: novel neuro-ectodermal targets and clinical indicators in small cell lung cancer. Cancer Immun 2005; 5 Suppl 1: 20. URL: http://www.cancerimmunity.org/ v5suppl1p20/041241_abs.htm
35. Jäger E. Vaccine strategies against NY-ESO-1 in cancer patients. Cancer Immun 2005; 5 Suppl 1: 12. URL: http://www.cancerimmunity.org/ v5suppl1p12/041233_abs.htm
36. Davis ID, Chen W, Schnurr M, Hopkins W, Miloradovic L, Old LJ, Maraskovsky E, Cebon JS. NY-ESO-1 protein-based cancer vaccines: the Melbourne experience. Cancer Immun 2005; 5 Suppl 1: 13. URL: http://www.cancerimmunity. org/v5suppl1p13/041234_abs.htm
37. Brichard V. Development of cancer vaccines with the MAGE-3 protein. CanCancer Immun 2005; 5 Suppl 1: 16. URL: http://www.cancerimmunity.org/ v5suppl1p16/041237_abs.htm
38. Slingluff CL Jr. Melanoma peptide vaccines: multipeptide approaches for targeting cytotoxic and helper T cells. Cancer Immun 2005; 5 Suppl 1: 24. URL: http://www.cancerimmunity.org/v5suppl1p24/041245_abs.htm
39. Schreiber H, Spiotto MT, Rowley DA. Targeting tumor stroma to destroy cancer variants. Cancer Immun 2005; 5 Suppl 1: 7. URL: http://www. cancerimmunity.org/v5suppl1p7/041228_abs.htm
40. Srivastava P. Specific immunogenicity of heat shock protein-peptide complexes: new developments. CCancer Immun 2005; 5 Suppl 1: 11. URL: http://www.cancerimmunity.org/v5suppl1p11/041232_abs.htm
41. Atanackovic D. Danger signals and the development of new cancer vaccine strategies. Cancer Immun 2005; 5 Suppl 1: 17. URL: http://www.cancerimmunity. org/v5suppl1p17/041238_abs.htm
42. Panicali D. The evolution of poxvirus based cancer vaccines. Cancer Immun 2005; 5 Suppl 1: 27. URL: http://www.cancerimmunity.org/v5suppl1p27/041248_abs. htm
43. Chen W, Jackson H, Dimopoulos N, Tai TY, Mifsud NA, Chen Q, Miloradovic L, Maraskovsky E, Old LJ, Davis ID, Cebon JS. Comprehensive analysis of T-cell responses after vaccination with NY-ESO-1 protein. Cancer Immun 2005; 5 Suppl 1: 14. URL: http://www.cancerimmunity.org/v5suppl1p14/041235_abs.htm
44. Speiser DE. Tumor-specific T cells induced in melanoma patients either naturally or by vaccination with peptides, IFA ± CpG oligodeoxynucleotides. Cancer Immun 2005; 5 Suppl 1: 23. URL: http://www.cancerimmunity.org/v5suppl1p23/041244_abs.htm
45. Coulie PG, Lurquin C, Lethé B, van Baren N, Boon T. Possible mechanisms of tumor regression after vaccination with MAGE antigens. Cancer Immun 2005; 5 Suppl 1: 15. URL: http://www.cancerimmunity.org/v5suppl1p15/ 041236_abs.htm
46. Odunsi K. Lessons from a pilot clinical trial of vaccine therapy with an NY-ESO-1 peptide of dual MHC class I and II specificities in ovarian cancer. Cancer Immun 2005; 5 Suppl 1: 22. URL: http://www.cancerimmunity.org/ v5suppl1p22/041243_abs.htm
47. Greenberg P, Ho W, Wolfl M, Teague R, Morimoto J, Dossett M, Blattman J. Isolating tumor-reactive T cells and making them work in tumor therapy. CanCancer Immun 2005; 5 Suppl 1: 25. URL: http://www.cancerimmunity.org/ v5suppl1p25/041246_abs.htm
48. Dranoff G. GM-CSF based cancer vaccines. Cancer Immun 2005; 5 Suppl 1: 26. URL: http://www.cancerimmunity.org/v5suppl1p26/041247_abs.htm
49. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
50. Wheelock EF, Weinhold KJ, Levich J. The tumor dormant state. Adv Cancer Res 1981; 34: 107-40.
51. Uhr JW, Tucker T, May RD, Siu H, Vitetta ES. Cancer dormancy: studies of the murine BCL1 lymphoma. Cancer Res 1991; 51: 5045s-53s.
52. Schreiber RD, Old LJ, Hayday AC, Smyth MJ. Response to 'A cancer immunosurveillance controversy'. Nat Immunol 2004; 5: 4-5.
53. Chan R, Bruce A, Cardi. R, Old LJ, Schreiber RD. Manuscript in preparation.
54. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95: 7556-61.
55. Bruce A, Schreiber RD. Manuscript in preparation.